Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEOMEX: Lenalidomide, melphalan, and dexamethasone in AL amyloidosis
NCT00883623Phase 2Completed
- Sponsor
- Heidelberg University
- Start
- Apr 2009
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in amyloid light chain amyloidosis, sponsored by Heidelberg University. Primary endpoint: Complete response rate at 6 months. Started Apr 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT00883623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00883623.